Integrating molecular markers into the World Health Organization classification of CNS tumors: A survey of the neuro-oncology community

Neuro-Oncology

Volumn 19, Issue 3, 2017, Pages 336-344

  Aldape, Kenneth ^a   Nejad, Romina ^a   Louis, David N ^b   Zadeh, Gelareh ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Classification; Molecular markers; Pathology

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER; BIOLOGICAL MARKER;

ADULT; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; HUMAN; NEUROLOGY; ONCOLOGY; REVIEW; SELF REPORT; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLASSIFICATION; METABOLISM; PRACTICE GUIDELINE; QUESTIONNAIRE; STANDARDS;

BIOMARKERS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; NEUROLOGY; PRACTICE GUIDELINES AS TOPIC; SURVEYS AND QUESTIONNAIRES; WORLD HEALTH ORGANIZATION;

EID: 85019733902     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now181     Document Type: Review

References (33)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
2. Louis DN OH, Wiestler OD, Cavenee WK. World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2007.
3. Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128(4):561-571.
4. Labussiere M, Boisselier B, Mokhtari K, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83(13):1200-1206.
5. Dubbink HJ, Atmodimedjo PN, Kros JM, et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol. 2016;18(3):388-400.
6. Hinrichs BH, Newman S, Appin CL, et al. Farewell to GBM-O: genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. Acta Neuropathol Commun. 2016;4(1):4.
7. Chamberlain MC, Born D. Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. J Neurooncol. 2015;125(2):249-251.
8. Leeper HE, Caron AA, Decker PA, et al. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget. 2015;6(30):30295-30305.
9. Taal W, van der Rijt CC, Dinjens WN, et al. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study I with growth kinetics. J Neurooncol. 2015;121(2):365-372.
10. Intergroup Radiation Therapy Oncology Group Trial, Cairncross G, Berkey B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24(18):2707-2714.
11. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free surviva but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24(18):2715-2722.
12. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-350
13. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343
14. Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer. 2013;49(16):3477-3485
15. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
16. Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550-563.
17. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481-2498
18. Buczkowicz P Hawkins C. Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma. Front Oncol. 2015;5:147.
19. Chamdine O, Gajjar A. Molecular characteristics of pediatric high-grade gliomas. CNS Oncol. 2014;3(6) 433-443
20. Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24(5):429-435
21. Louis DN. The next step in brain tumor classification: "Let us now praise famous men"... or molecules? Acta Neuropathol. 2012;124(6):761-762.
22. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473-1479.
23. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-715.
24. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-926.
25. Mur P, Rodriguez de Lope A, Diaz-Crespo FJ, et al. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. J Neurooncol. 2015;122(3):441-450
26. Pathak P, Jha P, Purkait S, et al. Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM. J Neurooncol. 2015;121(3):489-497.
27. Korshunov A, Ryzhova M, Hovestadt V, et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015;129(5):669-678.
28. Buczkowicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 2014;46(5):451-456.
29. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014;46(5):462-466.
30. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444-450.
31. Taylor KR, Mackay A, Truffaux N, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014;46(5):457-461.
32. Louis DN, Wiestler OD, Cavenee WK (eds.) World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2016.
33. Louis DN, Reifenberger G, von Deimling A, et al. The 2016 WHO classification of tumours of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803-820.